In re Application of:

Evan C. Unger

Application No.: 10/084,855 Filed: February 27, 2002

Page 2

Attorney Docket No.: IMARX1210-2

## IN THE CLAIMS

The following is the listing of the claims.

- 1. (Previously presented) A targeted therapeutic delivery system for the controlled delivery of a therapeutic compound to a region of a patient comprising, in combination with a therapeutic compound, stabilized lipid microspheres including:
  - (a) a drug-free outer lipid layer having a first surface and a second surface; and
- (b) a gas-free inner oil layer disposed over the first surface of the outer layer, wherein the inner layer defines void, the void containing a gas or gaseous precursor, wherein said lipid comprises at least one phosphatidic acid and the therapeutic compound is dispersed within the oil.
  - 2-46. (Canceled).
- 47. (Previously presented) The targeted therapeutic delivery system of claim 1 wherein said gas or gaseous precursor is selected from the group consisting of fluorine, perfluorocarbons, sulfurhexafluoride, and perfluoroethers.
  - 48. (Canceled).
- 49. (Previously presented) The targeted therapeutic delivery system of claim 1 wherein said lipid comprises at least one phosphatidylcholine, and at least one phosphatidylethanolamine.
- 50. (Previously presented) The targeted therapeutic delivery system of claim 49 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine,

In re Application of:

Evan C. Unger

Application No.: 10/084,855

Filed: February 27, 2002

Page 3

dipalmitoylphosphatidylcholine and distearoyl-phosphatidylcholine; said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine-PEG 5,000, dioleyl-phosphatidylethanolamine, and N-succinyl- dioleyl-phosphatidylethanolamine; and said phosphatidic acid is dipalmitoylphosphatidic acid.

Attorney Docket No.: IMARX1210-2

51. (Previously presented) The targeted therapeutic delivery system of claim 1 wherein said oil is selected from the group consisting of silicone oil, cod liver oil, mineral oil, plant oil, oil comprising fluorinated triglycerides, biocompatible saturated fatty acids, biocompatible unsaturated fatty acids, biocompatible partially hydrogenated fatty acids, silicon-based oils, and synthetic oils.

52-54. (Canceled).

55. (Previously presented) The targeted therapeutic delivery system of claim 51 wherein said synthetic oil is selected from the group consisting of triolein, trimyristin, triacetin, tripalmitin, tristearin, tributyrin, glyceryl monooctanoate, and glyceryl monostearate.

56-59. (Canceled).